Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,658 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Clear all
Recruiting Phase 2 Interventional

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

NCT05748834
View directory record Official record
Conditions
Breast Cancer
Interventions
Tucatinib, Doxil
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Columbia, Maryland • Bensalem, Pennsylvania • Nashville, Tennessee + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 27, 2026, 6:22 AM EDT
Completed No phase listed Observational

Acute Kidney Injury in Critically Ill Patients

NCT02765464
View directory record Official record
Conditions
Acute Renal Injury
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 27, 2026, 6:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions
Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 27, 2026, 6:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobile Sleep and Growth Study

NCT03263338
View directory record Official record
Conditions
Childhood Sleep Promotion
Interventions
Mobile Sleep and Growth Study
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 12 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 27, 2026, 6:22 AM EDT
Terminated Phase 3 Interventional Results available

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

NCT00968968
View directory record Official record
Conditions
Cancer
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
112
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 27, 2026, 6:22 AM EDT
Terminated Not applicable Interventional Results available

Targeted Breast Milk Fortification for Very Low Birth Weight Infants in the NICU

NCT04025021
View directory record Official record
Conditions
Human Milk, Neonate, Breast Milk
Interventions
Targeted Fortification, The Miris Human Milk Analyzer
Dietary Supplement · Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
Up to 6 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 27, 2026, 6:22 AM EDT
Recruiting Phase 2 Interventional

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

NCT07222215
View directory record Official record
Conditions
Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2- Breast Cancer, ESR1 Gene Mutation, ER Wildtype, Breast Neoplasms
Interventions
Capecitabine, Elacestrant
Drug
Lead sponsor
Kristina A. Fanucci
Other
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 27, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Point-of-Care Adipose-derived Cells for Hair Growth

NCT02729415
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Stromal Vascular Fraction Cells (SVF Cells) Injection, Liposuction, Hair Measurements
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 27, 2026, 6:22 AM EDT
Enrolling by invitation No phase listed Observational

Molecular Modulation of the Growth Plate

NCT03501589
View directory record Official record
Conditions
Growth Plate Injury
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 27, 2026, 6:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Growth and Safety of a Low Lactose Milk-Based Infant Formula

NCT01497314
View directory record Official record
Conditions
Growth, Healthy Term Infants
Interventions
Low Lactose Infant Formula
Other
Lead sponsor
Perrigo Nutritionals
Industry
Eligibility
Up to 14 Days
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
6
States / cities
Melbourne, Florida • Haughton, Louisiana • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 27, 2026, 6:22 AM EDT
Completed Phase 2 Interventional

MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer

NCT00799240
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Arm A: Pemetrexed Cisplatin, Arm B Pemetrexed, Cisplatin and MK-0646
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Hutchinson, Kansas • Kansas City, Kansas • Topeka, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2014 · Synced Oct 27, 2026, 6:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes

NCT04633551
View directory record Official record
Conditions
Pre-Eclampsia, Pre-Term, Intrauterine Growth Restriction, Hypertension in Pregnancy
Interventions
Anti-inflammatory supplement
Dietary Supplement
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 27, 2026, 6:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study

NCT03709381
View directory record Official record
Conditions
Adrenal Insufficiency, Osteopenia, Osteoporosis, Steroid Suppression of ACTH Secretion
Interventions
Low Dose Cosyntropin (ACTH) stimulation test, High Dose Cosyntropin (ACTH) stimulation test
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 27, 2026, 6:22 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Loss of Y Chromosome in Aortic Stenosis

NCT06595407
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Blood analysis for loss-of-Y chromosome
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
40 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

Iressa Study in Patients With Salivary Gland Cancer

NCT00509002
View directory record Official record
Conditions
Salivary Gland Cancer
Interventions
Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 27, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain

NCT01530126
View directory record Official record
Conditions
Periodontitis
Interventions
B-TCP + 0.3 mg/ml rhPDGF-BB in buffer, B-TCP + 1.0 mg/ml rhPDGF-BB in buffer, B-TCP +buffer
Biological
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 27, 2026, 6:22 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Biomarkers Related to Bone in Pediatric Gaucher Disease

NCT06116071
View directory record Official record
Conditions
Gaucher Disease, Bone Diseases
Interventions
Not listed
Lead sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Other
Eligibility
5 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 27, 2026, 6:22 AM EDT
Completed No phase listed Observational Results available

Acromegaly Treatment Quality of Life Study

NCT01732406
View directory record Official record
Conditions
Acromegaly
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 27, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional Results available

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

NCT04489940
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Bintrafusp alfa
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Newark, Delaware • Jacksonville, Florida • Silver Spring, Maryland + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 27, 2026, 6:22 AM EDT
Recruiting Not applicable Interventional

Maternal Left Lateral Position in Fetal Growth Restriction

NCT06919692
View directory record Official record
Conditions
Fetal Growth Restriction
Interventions
Left lateral recumbent positioning
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 27, 2026, 6:22 AM EDT
Completed Phase 2 Interventional

Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome

NCT00001221
View directory record Official record
Conditions
Gonadal Dysgenesis, Turner's Syndrome
Interventions
Growth Hormone (Humatrope)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 6:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation

NCT01850706
View directory record Official record
Conditions
Detrusor Overactivity
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 27, 2026, 6:22 AM EDT
Completed No phase listed Observational

National Children s Health Study

NCT00852904
View directory record Official record
Conditions
Infant, Child Development, Biological Samples
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older
Enrollment
9,942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 27, 2026, 6:22 AM EDT
Recruiting Not applicable Interventional

A Prospective Analysis of Long-Term Clinical Outcomes and 3D Spine Growth in Anterior Vertebral Body Tethering

NCT04914507
View directory record Official record
Conditions
Scoliosis Idiopathic
Interventions
Anterior Vertebral Body Tethering
Device
Lead sponsor
Pediatric Spine Foundation
Other
Eligibility
Up to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Saint Paul, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 6:22 AM EDT